Opinion
Video
Panelists summarize key takeaways on using bispecific antibodies for multiple myeloma treatment.
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
FDA Approves Linvoseltamab-Gcpt for Treatment of Relapsed or Refractory Multiple Myeloma
2 Commerce Drive
Cranbury, NJ 08512